AA
TARA icon

ALPS Advisors’s Protara Therapeutics TARA Stock Holding History

ALPS Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Buy
57,041
+13,012
+30% +$61.9K ﹤0.01% 1152
2026
Q1 		$229K Buy
44,029
+1,640
+4% +$9.71K ﹤0.01% 988
2025
Q4 		$226K Buy
+42,389
New +$236K ﹤0.01% 965
2021
Q2 		– Sell
-20,279
Closed -$319K – 917
2021
Q1 		$319K Buy
20,279
+209
+1% +$3.88K ﹤0.01% 782
2020
Q4 		$486K Buy
+20,070
New +$433K 0.01% 502

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

ALPS Advisors's TARA Position: Q2 2026 in Review

ALPS Advisors increased its Protara Therapeutics (TARA) stake by 30% in Q2 2026, buying an estimated $61.9K and bringing the position to 57,041 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

ALPS Advisors first reported a position in TARA in Q4 2020 and has held it in 5 quarters since. The position peaked at $486K in Q4 2020. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • ALPS Advisors held 57,041 shares of Protara Therapeutics worth $218K as of Q2 2026.
  • ALPS Advisors bought 13,012 Protara Therapeutics shares in Q2 2026, an estimated $61.9K.
  • Protara Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1152 holding.
  • ALPS Advisors first reported a position in Protara Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • ALPS Advisors's Protara Therapeutics position peaked at $486K in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.